

# Timothy W Synold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4347050/publications.pdf>

Version: 2024-02-01

104  
papers

4,885  
citations

101496

36  
h-index

98753

67  
g-index

104  
all docs

104  
docs citations

104  
times ranked

6326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/II first-in-human CAR Tâ€“targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1130-TPS1130.	0.8	3
2	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. Pleura and Peritoneum, 2022, 7, 169-177.	0.5	2
3	EVEREST: Everolimus for renal cancer ensuing surgical therapyâ€“A phase III study (SWOG S0931,) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	29
4	Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients. Cancer Gene Therapy, 2021, 28, 294-306.	2.2	7
5	Development and validation of an LCâ€“MS/MS generic assay platform for small molecule drug bioanalysis. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114185.	1.4	2
6	Systemic Antiâ€“PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. JAMA Oncology, 2020, 6, 1947.	3.4	28
7	In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17535-17542.	3.3	15
8	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 485-489.	0.7	2
9	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e667-e672.	0.2	6
10	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 1034-1044.	3.2	48
11	Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo. Blood, 2020, 136, 22-23.	0.6	0
12	Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer, 2019, 3, 111-118.	0.2	8
13	Single-cell RNA-sequencing analysis of estrogen- and endocrine-disrupting chemical-induced reorganization of mouse mammary gland. Communications Biology, 2019, 2, 406.	2.0	36
14	Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma. Frontiers in Oncology, 2019, 9, 68.	1.3	30
15	Molecular Mechanisms of Polybrominated Diphenyl Ethers (BDE-47, BDE-100, and BDE-153) in Human Breast Cancer Cells and Patient-Derived Xenografts. Toxicological Sciences, 2019, 169, 380-398.	1.4	30
16	8â€“chloroâ€“adenosine activity in FLT3â€“ITD acute myeloid leukemia. Journal of Cellular Physiology, 2019, 234, 16295-16303.	2.0	12
17	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. Oncologist, 2019, 24, 1137-1145.	1.9	2
18	Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Advances, 2019, 3, 1027-1032.	2.5	14

#	ARTICLE	IF	CITATIONS
19	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 589-598.	1.1	16
20	HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
21	A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. <i>British Journal of Haematology</i> , 2018, 180, 445-448.	1.2	4
22	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. <i>Clinical Cancer Research</i> , 2018, 24, 6053-6065.	3.2	27
23	A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 723-732.	1.1	5
24	Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 67-76.	2.0	18
25	Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 2951-2960.	3.2	121
26	Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. <i>Oncologist</i> , 2017, 22, 1189-1196.	1.9	3
27	Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 101.	2.2	7
28	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	0.8	12
29	A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: a California Cancer Consortium study. <i>Leukemia and Lymphoma</i> , 2016, 57, 2307-2314.	0.6	6
30	A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for <i>Agaricus bisporus</i> -induced prostate-specific antigen responses. <i>Cancer</i> , 2015, 121, 2942-2950.	2.0	44
31	Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 495-503.	1.1	16
32	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	1.1	27
33	Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age. <i>Oncologist</i> , 2015, 20, 37-44.	1.9	18
34	Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2553-2553.	0.8	8
35	Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. <i>British Journal of Cancer</i> , 2014, 111, 2268-2274.	2.9	14
36	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014, 38, 988-996.	0.4	40

#	ARTICLE	IF	CITATIONS
37	A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. <i>Journal of Neuro-Oncology</i> , 2014, 118, 169-177.	1.4	22
38	First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. <i>Investigational New Drugs</i> , 2013, 31, 986-1000.	1.2	187
39	A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 85-91.	1.1	3
40	A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. <i>European Journal of Cancer</i> , 2013, 49, 1634-1640.	1.3	16
41	Neural Stem Cell-Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. <i>Science Translational Medicine</i> , 2013, 5, 184ra59.	5.8	194
42	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
43	Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts. <i>Free Radical Biology and Medicine</i> , 2013, 57, 162-175.	1.3	36
44	Neural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications for Clinical Use. <i>Stem Cells Translational Medicine</i> , 2013, 2, 983-992.	1.6	58
45	Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2013, 19, 3631-3639.	3.2	59
46	Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4562-4565.	1.4	10
47	Bioimaging Real-Time PXR-Dependent <i>mdr1a</i> Gene Regulation in <i>mdr1a</i> .fLUC Reporter Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 438-445.	1.3	13
48	A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance. <i>Cancer Research</i> , 2013, 73, 6484-6493.	0.4	64
49	Phase I study of nelfinavir in liposarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 791-799.	1.1	29
50	Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 617-625.	1.1	29
51	A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1347-1355.	0.8	14
52	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP,) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 835-843.	1.1	35
53	Antivirulence Potential of TR-700 and Clindamycin on Clinical Isolates of <i>Staphylococcus aureus</i> Producing Phenol-Soluble Modulins. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4432-4435.	1.4	13
54	Baicalin increases VEGF expression and angiogenesis by activating the ERR $\alpha$ /PGC-1 $\alpha$ pathway. <i>Cardiovascular Research</i> , 2011, 89, 426-435.	1.8	80

#	ARTICLE	IF	CITATIONS
55	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 927-933.	1.1	14
56	Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2043-2054.	0.9	8
57	A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5394-5399.	3.3	23
58	The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation. <i>Clinical Cancer Research</i> , 2009, 15, 7092-7098.	3.2	194
59	Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2163-2169.	0.8	59
60	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1149-1155.	1.1	11
61	A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. <i>Investigational New Drugs</i> , 2008, 26, 249-255.	1.2	76
62	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2008, 26, 257-264.	1.2	74
63	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). <i>Investigational New Drugs</i> , 2008, 26, 265-272.	1.2	60
64	Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2â€²-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 363-368.	1.1	67
65	Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 103-109.	0.9	46
66	Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib. <i>Cancer Investigation</i> , 2008, 26, 53-59.	0.6	26
67	Advanced Glycation End Products of DNA: Quantification of N2-(1-Carboxyethyl)-2â€²-deoxyguanosine in Biological Samples by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2008, 21, 2148-2155.	1.7	58
68	Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. <i>Clinical Cancer Research</i> , 2007, 13, 1232-1237.	3.2	35
69	Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 3660-3666.	3.2	48
70	Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function. <i>Clinical Cancer Research</i> , 2007, 13, 4832-4839.	3.2	61
71	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 549-557.	1.1	4
72	Oblimersen and Î±-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 705-711.	1.2	13

#	ARTICLE	IF	CITATIONS
73	Renoprotective and Lipid-Lowering Effects of LR Compounds, Novel Advanced Glycation End Product Inhibitors, in Streptozotocin-Induced Diabetic Rats. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 767-776.	1.8	14
74	Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 533-544.	1.7	21
75	The Effect of Height on Paclitaxel Nerve Damage. <i>Journal of Neuro-Oncology</i> , 2005, 74, 207-210.	1.4	3
76	The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial. <i>Clinical Cancer Research</i> , 2005, 11, 4444-4450.	3.2	97
77	DNA lesions induced by UV A1 and B radiation in human cells: Comparative analyses in the overall genome and in the p53 tumor suppressor gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10058-10063.	3.3	139
78	Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel. <i>Clinical Cancer Research</i> , 2004, 10, 461-467.	3.2	73
79	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96h for the treatment of advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 241-248.	1.1	7
80	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 283-289.	1.1	9
81	G-to-T Transversions and Small Tandem Base Deletions Are the Hallmark of Mutations Induced by Ultraviolet A Radiation in Mammalian Cells. <i>Biochemistry</i> , 2004, 43, 8169-8177.	1.2	76
82	Similar Mutagenicity of Photoactivated Porphyrins and Ultraviolet A Radiation in Mouse Embryonic Fibroblasts: Involvement of Oxidative DNA Lesions in Mutagenesis. <i>Biochemistry</i> , 2004, 43, 15557-15566.	1.2	36
83	Effect of valsopodar on the pharmacokinetics of unbound paclitaxel. <i>Investigational New Drugs</i> , 2003, 21, 291-298.	1.2	10
84	Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. <i>Seminars in Oncology</i> , 2003, 30, 14-19.	0.8	61
85	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003, 17, 184-194.	0.9	13
86	Stability and Antibacterial Activity of Cefepime during Continuous Infusion. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1991-1994.	1.4	38
87	Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. <i>Clinical Cancer Research</i> , 2003, 9, 5896-901.	3.2	57
88	Development of Population Pharmacokinetic Models and Optimal Sampling Times for Ibuprofen Tablet and Suspension Formulations in Children With Cystic Fibrosis. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 315-321.	1.0	10
89	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 353-359.	1.1	9
90	Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. <i>Blood</i> , 2001, 97, 2839-2845.	0.6	50

#	ARTICLE	IF	CITATIONS
91	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 327-332.	1.1	9
92	Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. <i>Investigational New Drugs</i> , 2001, 19, 335-340.	1.2	74
93	The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. <i>Nature Medicine</i> , 2001, 7, 584-590.	15.2	798
94	Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXR. <i>Journal of Biological Chemistry</i> , 2001, 276, 33309-33312.	1.6	168
95	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 403-410.	1.1	8
96	Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 103-110.	1.1	31
97	High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 504-508.	1.1	10
98	Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 1997, 336, 1781-1787.	13.9	158
99	Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity. <i>Molecular Pharmacology</i> , 1997, 52, 155-163.	1.0	95
100	Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1996, 683, 245-249.	1.7	2
101	Role of Folylpolygutamate Synthetase (FPGS) in Antifolate Chemotherapy; a Biochemical and Clinical Update. <i>Leukemia and Lymphoma</i> , 1996, 21, 9-15.	0.6	19
102	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1994, 125, 642-649.	0.9	119
103	Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 31, 229-239.	1.1	208
104	Pharmacologic Basis for High-dose Chemotherapy. , 0, , 287-315.		4